More states are focusing on cancer biomarker testing for payer coverage requirements.
Oncology and Cancer Care
Recent research into liquid biopsies has resulted in a new blood test that can detect liver cancer while it is still in an early stage.
Hospitals and oncology groups may be able to apply modern precision medicine principles to a 50-year-old cancer drug, increasing the drug’s effectiveness for breast cancer patients.
Method genetically defines patients who would benefit from intensifying the chemotherapy, adding a new drug, or having chemotherapy reduced to avoid toxicity.
Researchers at Weill Cornell Medicine believe they have discovered the variant protein that causes taxane-resistant cancer cells to develop.
By using organoids, “we can show that for a particular patient subset, for a particular drug, we can do better than the current selection criteria,” stated Else Driehuis, PhD.
The approach combined deep molecular profiling with comprehensive drug sensitivity testing for patients where standard therapy alternatives had been exhausted.
A recently FDA-recognized somatic cancer database organizes tumor genomic profiling and cancer drugs into levels of clinical evidence that can be used by hospital and oncology leaders.
Comprehensive assessment of young adult tumors across multiple cancer types reveals age-related cancer genetics that are important to treatment decisions.
Renewed interest in abandoned drugs for specific subsegments of certain healthcare populations could lead to new personalized treatments for cancer and other chronic diseases.